Title	Overall response rate
Number of Patients Screened	28
Number of Patients Enrolled	26
Number of Patients Evaluable for Toxicity	25
Number of Patients Evaluated for Efficacy	25
Evaluation Method	RECIST 1.1
Response Assessment CR	n = 0 (0%)
Response Assessment PR	n = 0 (0%)
Response Assessment SD	n = 14 (56%)
Response Assessment PD	n = 10 (40%)
Response Assessment OTHER	n = 1 (4%)
Title	Progression‐free and overall survival
Number of Patients Screened	28
Number of Patients Enrolled	26
Number of Patients Evaluable for Toxicity	25
Number of Patients Evaluated for Efficacy	25
(Median) Duration Assessments PFS	2.8 months, CI: 1.3–4.0
(Median) Duration Assessments OS	6.3 months, CI: 5.7–11.1